DeepMed Research

AFFiRiS AG

🇦🇹Austria

Country: 🇦🇹Austria

Ownership: Holding

Established: 2003-01-01

Employees: 101

Market Cap: -

Website: http://www.affiris.com

Clinical Trials

Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

Phase 1

Withdrawn

Conditions: Parkinson's Disease

Interventions: Biological: AFFITOPE® PD01A + Adjuvant
Biological: Adjuvant without active component

First Posted Date: 2016-05-02

Last Posted Date: 2016-08-05

Lead Sponsor: Affiris AG

Registration Number: NCT02758730

Locations: 🇩🇪
University Hospital Tübingen, Tübingen, Germany

Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Biological: AFFITOPE® PD01A

First Posted Date: 2015-12-02

Last Posted Date: 2017-06-05

Lead Sponsor: Affiris AG

Target Recruit Count: 26

Registration Number: NCT02618941

Locations: 🇦🇹
Studienzentrum der PROSENEX, AmbulatoriumsbetriebsgesmbH an der Confraternität-Privatklinik Josefstadt, Vienna, Austria

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

Phase 1

Completed

Conditions: Hypercholesterolemia

Interventions: Biological: AFFITOPE® AT06A+adjuvant
Biological: Adjuvant without active component
Biological: AFFITOPE® AT04A+adjuvant

First Posted Date: 2015-07-27

Last Posted Date: 2017-10-20

Lead Sponsor: Affiris AG

Target Recruit Count: 72

Registration Number: NCT02508896

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA

Phase 1

Completed

Conditions: Neurodegenerative Diseases
Multiple System Atrophy

Interventions: Biological: AFFITOPE® PD03A + Adjuvant
Biological: AFFITOPE® PD01A + Adjuvant
Biological: Adjuvant without active component

First Posted Date: 2014-10-21

Last Posted Date: 2017-06-05

Lead Sponsor: Affiris AG

Target Recruit Count: 30

Registration Number: NCT02270489

Locations: 🇫🇷
University Hospital Bordeaux (Pellegrin Hospital), Bordeaux Cedex, France
🇫🇷
University Hospital Toulouse, Toulouse Cedex 9, France

Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease

Phase 1

Completed

Conditions: Neurodegenerative Diseases
Parkinson Disease

Interventions: Biological: Low dose AFFITOPE® PD03A + Adjuvant
Biological: High dose AFFITOPE® PD03A + Adjuvant
Biological: Adjuvant without active component

First Posted Date: 2014-10-17

Last Posted Date: 2016-10-31

Lead Sponsor: Affiris AG

Target Recruit Count: 36

Registration Number: NCT02267434

Locations: 🇦🇹
Medical University Innsbruck, Department of Neurology, Innsbruck, Austria
🇦🇹
Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität -Privatklinik Josefstadt, Vienna, Austria

Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Biological: AFFITOPE® PD01A
Other: Control

First Posted Date: 2014-08-13

Last Posted Date: 2015-08-17

Lead Sponsor: Affiris AG

Target Recruit Count: 28

Registration Number: NCT02216188

Locations: 🇦🇹
Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität-Privatklinik Josefstadt, Skodagasse 32, 1080 Vienna, Vienna, Austria

Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006

Phase 2

Terminated

Conditions: Alzheimer´s Disease

Interventions: Biological: AFFITOPE® AD02
Biological: Placebo

First Posted Date: 2013-12-11

Last Posted Date: 2015-06-24

Lead Sponsor: Affiris AG

Target Recruit Count: 194

Registration Number: NCT02008513

Locations: 🇭🇷
Opća bolnica Varaždin, Klinika za Neurologiju, Varaždin, Croatia
🇨🇿
University Hospital Motol, Clinic of Neurology, Praha, Czech Republic
🇫🇷
CMRR Hôpital Pellegrin, Bâtiment USN Tastet Girard, Bordeaux Cedex, France

and more 24 locations

AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immunization With AFFITOPE® PD01A

Completed

Conditions: Parkinson's Disease

First Posted Date: 2013-06-25

Last Posted Date: 2015-08-17

Lead Sponsor: Affiris AG

Target Recruit Count: 30

Registration Number: NCT01885494

Locations: 🇦🇹
Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität-Privatklinik Josefstadt, Skodagasse 32, Vienna, Austria

Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A

Terminated

Conditions: Alzheimer's Disease

First Posted Date: 2012-04-02

Last Posted Date: 2013-11-06

Lead Sponsor: Affiris AG

Target Recruit Count: 16

Registration Number: NCT01568086

Locations: 🇦🇹
Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an derConfraternität-Privatklinik Josefstadt, Vienna, Austria
🇦🇹
Medical University of Vienna, Department for Psychiatry and Psychotherapy, Wien, Austria

Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Biological: AFFITOPE® PD01A
Other: Control

First Posted Date: 2012-04-02

Last Posted Date: 2015-08-17

Lead Sponsor: Affiris AG

Target Recruit Count: 32

Registration Number: NCT01568099

Locations: 🇦🇹
Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität-Privatklinik Josefstadt, Skodagasse 32, 1080 Vienna, Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy